Gerald Li

10PUBLICATIONS

54CO-AUTHORS

Predictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (10)

Sort by Publication Date:

|May 14, 2026

Homozygous Loss of Recombination Repair Genes and Poly ADP-Ribose Polymerase Inhibitor Benefit for Patients With Ovarian Cancer.

|Dec 04, 2025

Additive Clinical Utility of Microsatellite Instability and Tumor Mutational Burden to Predict Immune Checkpoint Inhibitor Effectiveness in Metastatic Castration-Resistant Prostate Cancer.

Nicolas Sayegh, Ryon P Graf, Umang Swami

|Oct 09, 2025

LRP1b Loss Predicts Sensitivity to Immunotherapy in Patients with NSCLC: An Analysis of the Phase III CheckMate-026 Randomized Trial.

Andrew J Armstrong, Hilary Dietz, David Balli

|Jun 23, 2025

Clinical utility of companion diagnostic biomarker results below the limit of detection in comprehensive genomic profiling of patients with advanced non-small cell lung cancer.

Gerald Li, Stephanie B Greene, Baljinder Kaur

|Jun 16, 2025

Association of Homologous Recombination Repair Alterations with Outcomes in Patients with Metastatic Hormone-Sensitive Prostate Cancer.

Chadi Hage Chehade, Ryon P Graf, Zeynep Irem Ozay

|Jul 30, 2024

Effectiveness of PARP Inhibitor Maintenance Therapy in Ovarian Cancer by BRCA1/2 and a Scar-Based HRD Signature in Real-World Practice.

Debra L Richardson, Julia C F Quintanilha, Natalie Danziger

Pageof 2

Frequent Collaborators

Ryon P Graf

Richard S P Huang

Jeffrey S Ross

Umang Swami

Douglas Lin

Alexa B Schrock

Nicolas Sayegh

Neeraj Agarwal

Julia Elvin

Geoffrey R Oxnard

Frequent Collaborators

Ryon P Graf

Richard S P Huang

Jeffrey S Ross

Umang Swami